Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,101 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,794 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06195891 | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02211755 | Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2026 |
| clinicaltrials |
| NCT04898894 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | active not recruiting | Phase 1 | 37 | St. Jude Children's Research HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05396859 | Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | active not recruiting | Phase 1 | 13 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06129734 | Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | recruiting | Phase 1 / Phase 2 | 20 | Benjamin TomlinsonOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03068819 | Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 62 | Washington University School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03878199 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | terminated | Phase 1 / Phase 2 | 12 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03633955 | Pilot Imaging Study of Leukemia(REALIZE) | recruiting | Phase 1 | 60 | University of OklahomaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04435691 | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05428969 | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies(BEXMAB) | active not recruiting | Phase 1 / Phase 2 | 181 | Faron Pharmaceuticals LtdINDUSTRY | 3 | Apr 23, 2026 | clinicaltrials |
| NCT03009240 | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05101551 | Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy(PARPAML) | recruiting | Phase 1 | 34 | Norman J. LacayoOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07320235 | Imetelstat Combinations in Relapsed AML(IMAGINE) | recruiting | Phase 1 | 36 | Douglas TremblayOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05222984 | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | active not recruiting | Phase 1 | 17 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02390635 | PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 1 | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04797767 | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | recruiting | Phase 1 / Phase 2 | 62 | University of WashingtonOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics(BHARAT-1) | terminated | Phase 1 | 27 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06034002 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | recruiting | Phase 1 | 290 | Incyte CorporationINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04140487 | Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm | recruiting | Phase 1 / Phase 2 | 97 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07532824 | Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS(UHKT-PTC-TMI-1) | recruiting | Phase 1 / Phase 2 | 16 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03132454 | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | active not recruiting | Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06839456 | Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT | recruiting | Phase 1 / Phase 2 | 100 | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03192397 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06561152 | Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML | recruiting | Phase 1 / Phase 2 | 20 | Stanford UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529951 | Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers | not yet recruiting | Phase 1 | 60 | Eilean TherapeuticsINDUSTRY | 0 | Apr 14, 2026 | clinicaltrials |
| NCT05732103 | A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes | recruiting | Phase 1 / Phase 2 | 225 | Chordia Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06047886 | UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy | recruiting | Phase 1 | 50 | University of Alabama at BirminghamOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06146257 | A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes | recruiting | Phase 1 | 48 | GluBio Therapeutics Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05263271 | Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 58 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511062 | Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML | not yet recruiting | Phase 1 | 32 | Northside Hospital, Inc.OTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02204085 | A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 33 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03431090 | Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia | active not recruiting | Phase 1 / Phase 2 | 20 | Nationwide Children's HospitalOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 / Phase 2 | 12 | CRISPR TherapeuticsINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03793478 | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | active not recruiting | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 10 | Apr 1, 2026 | clinicaltrials |
| NCT04279847 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms(LIMBER) | active not recruiting | Phase 1 | 140 | Incyte CorporationINDUSTRY | 8 | Apr 1, 2026 | clinicaltrials |
| NCT05304377 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia(CML) | recruiting | Phase 1 | 250 | Enliven TherapeuticsINDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT06327685 | Avapritinib With Decitabine in Patients With SM-AHN | recruiting | Phase 1 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04716452 | Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia(KNAN2001) | recruiting | Phase 1 | 15 | Keystone Nano, IncINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02333162 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | suspended | Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04980404 | Inqovi Maintenance Therapy in Myeloid Neoplasms | active not recruiting | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05933070 | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML(LAUREL) | terminated | Phase 1 | 2 | Inmune Bio, Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT06563804 | A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML | terminated | Phase 1 / Phase 2 | 13 | Servier Bio-Innovation LLCINDUSTRY | 6 | Mar 30, 2026 | clinicaltrials |
| NCT00819546 | RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | active not recruiting | Phase 1 | 29 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03533816 | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | recruiting | Phase 1 | 38 | University of Kansas Medical CenterOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06313437 | Revumenib in Combination With 7+3 + Midostaurin in AML | recruiting | Phase 1 | 22 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07107126 | Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes | recruiting | Phase 1 | 24 | Remedy Plan, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | recruiting | Phase 1 / Phase 2 | 606 | Sumitomo Pharma America, Inc.INDUSTRY | 12 | Mar 24, 2026 | clinicaltrials |
| NCT04990102 | Phase IB/II of CPX-351 for Relapse Prevention in AML | recruiting | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07486726 | Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04278768 | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | suspended | Phase 1 / Phase 2 | 366 | Curis, Inc.INDUSTRY | 8 | Mar 19, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 29, 2026source: clinicaltrials